N,N-Dimethyltryptamine
IND- Indications
- Major depressive disorder
Company intelligence / Profile preview
Empyrean Neuroscience
New York City, New York, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company is developing genetically engineered neuroactive compounds from fungi and plants. As of the latest information, they were conducting IND-enabling studies for their first genetically engineered encapsulated mushroom drug product.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesfungal alkaloidscannabinoidsneuroactive compounds (including N,N-Dimethyltryptamine (DMT))
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Empyrean Neuroscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empyrean Neuroscience.